What In The World Is Going On With Benetic Biopharma (BNTC) Stock

Benetic Biopharma Inc BNTC shares are trading higher by 46.35% to $0.29 Monday morning after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy.

What Happened?

Benitec Biopharma has received FDA clearance for its Investigational New Drug (IND) application for BB-301, a gene therapy targeting Oculopharyngeal Muscular Dystrophy-related Dysphagia. Oculopharyngeal Muscular Dystrophy is a life-threatening genetic disorder affecting thousands of patients worldwide.

See Also: Tesla Crashes After Hitting Key Resistance

Benitec Biopharma says BB-301 represents a potential breakthrough in treating the debilitating symptoms of this condition. Subjects from Benitec's ongoing NH study will have the opportunity to participate in the Phase 1b/2a clinical study of BB-301, with interim safety and efficacy data expected at regular intervals.

The company says this milestone marks a significant advancement for both Benitec and patients with OPMD-related Dysphagia.

According to data from Benzinga Pro, BNTC has a 52-week high of $2.10 and a 52-week low of $0.13.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny Stockswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!